

## FOR IMMEDIATE RELEASE

Contact: Karl Uhlendorf

(202) 835-3460

### PhRMA Elects Three New Members to Board of Directors

*Deirdre P. Connelly, President, North America Pharmaceuticals, GlaxoSmithKline*

*Paul R. Fonteyne, President and Chief Executive Officer, Boehringer Ingelheim USA*

*Ulf A. Wiinberg, President and Chief Executive Officer, Lundbeck Pharmaceuticals*

**Washington, D.C. (February 7, 2012)** — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today the election of GlaxoSmithKline North America Pharmaceuticals President Deirdre P. Connelly, Boehringer Ingelheim USA President and CEO Paul R. Fonteyne, and Lundbeck Pharmaceuticals President and CEO Ulf A. Wiinberg to its Board of Directors.

“We are pleased to welcome three biopharmaceutical heavyweights – Ms. Connelly, Mr. Fonteyne, and Mr. Wiinberg – to PhRMA’s Board of Directors,” said PhRMA President and CEO John J. Castellani. “Their broad knowledge of the biopharmaceutical research sector will be instrumental in our efforts to advance public policies that encourage medical innovation, foster access for patients, and help the U.S. maintain its global leadership in medical discovery.”

Deirdre Connelly was named President, North America Pharmaceuticals, for GlaxoSmithKline in February 2009. Prior to joining GSK, Ms. Connelly spent 26 years with Eli Lilly and Company, where she held a variety of executive positions, most recently as President of Lilly USA. For six consecutive years (2006 - 2011), she has been recognized by *Fortune* magazine as one of the 50 most powerful women in business. In April 2010, she was named Woman of the Year by the Healthcare Businesswomen’s Association.

In 2008, Ms. Connelly was appointed to the President’s Commission on White House Fellowships. In this role, she helps to select the White House Fellows, a prestigious annual program that fosters leadership and public service. Ms. Connelly earned a B.S. in economics and marketing from Lycoming College, and is a graduate of Harvard University’s Advanced Management Program.

Paul Fonteyne was named U.S. Country Managing Director and President and CEO of Boehringer Ingelheim USA in January 2012. He previously served as Corporate Senior Vice President, responsible for leading the global marketing strategy supporting Boehringer Ingelheim’s Prescription Medicines business. In this role he helped drive growth in the company’s core areas of respiratory and cardiovascular disease, as well as positioned it to successfully enter new areas of diabetes and oncology. Prior to joining Boehringer Ingelheim in 2003, he held positions at Abbott Laboratories and Merck.

Mr. Fonteyne is a past Chairman of the National Pharmaceutical Council, an industry group focused on demonstrating the value of pharmaceutical products. He earned an MS in Chemical Engineering from the University of Brussels and an MBA from Carnegie Mellon University.

Ulf Wiinberg serves as President and CEO of Lundbeck, a role he has held since June 2008. Prior to joining Lundbeck, Mr. Wiinberg held a variety of executive positions at Wyeth Pharmaceuticals Europe, most recently as President of Wyeth Europe, Middle East, Africa and Canada, and served as a member of Wyeth’s Corporate Management Committee. Mr. Wiinberg’s pharmaceutical career began in 1981, when he joined American Cyanamid’s Lederle division in Sweden, holding a number of sales, marketing, and general management positions with responsibilities overseas and in the United States.

Mr. Wiinberg serves as Chairman of the World Self-Medication Industry Association. He has participated in the UK's task force for creating a more competitive pharmaceutical industry. Mr. Wiinberg also serves on the Board of the European Federation of Pharmaceutical Industries and Associations, and on the Council of the International Federation of Pharmaceutical Manufacturers and Associations.

###

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated \$49.4 billion in 2010 in discovering and developing new medicines. Industry-wide research and investment reached a record \$67.4 billion in 2010.

Find PhRMA Online:

- Website – <http://www.phrma.org>
- facebook – [www.facebook.com/PhRMA](http://www.facebook.com/PhRMA)
- Blog – [www.phrma.org/catalyst](http://www.phrma.org/catalyst)
- Twitter – [www.Twitter.com/PhRMA](http://www.Twitter.com/PhRMA) and [www.Twitter.com/PhRMApress](http://www.Twitter.com/PhRMApress)
- YouTube – [www.youtube.com/PhRMApress](http://www.youtube.com/PhRMApress)

For information on how innovative medicines save lives, visit: <http://www.innovation.org>

For information on the Partnership for Prescription Assistance, visit: <http://www.pparx.org>

For information on ensuring the flow of medicines during public health emergencies, visit <http://www.rxresponse.org>